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Abstract
Background: The lack of standardized criteria for defining chronic fatigue syndrome (CFS) has constrained
research. The objective of this study was to apply the 1994 CFS criteria by standardized reproducible criteria.
Methods: This population-based case control study enrolled 227 adults identified from the population of Wichita
with: (1) CFS (n = 58); (2) non-fatigued controls matched to CFS on sex, race, age and body mass index (n = 55);
(3) persons with medically unexplained fatigue not CFS, which we term ISF (n = 59); (4) CFS accompanied by
melancholic depression (n = 27); and (5) ISF plus melancholic depression (n = 28). Participants were admitted to
a hospital for two days and underwent medical history and physical examination, the Diagnostic Interview
Schedule, and laboratory testing to identify medical and psychiatric conditions exclusionary for CFS. Illness
classification at the time of the clinical study utilized two algorithms: (1) the same criteria as in the surveillance
study; (2) a standardized clinically empirical algorithm based on quantitative assessment of the major domains of
CFS (impairment, fatigue, and accompanying symptoms).
Results: One hundred and sixty-four participants had no exclusionary conditions at the time of this study.
Clinically empirical classification identified 43 subjects as CFS, 57 as ISF, and 64 as not ill. There was minimal
association between the empirical classification and classification by the surveillance criteria. Subjects empirically
classified as CFS had significantly worse impairment (evaluated by the SF-36), more severe fatigue (documented
by the multidimensional fatigue inventory), more frequent and severe accompanying symptoms than those with
ISF, who in turn had significantly worse scores than the not ill; this was not true for classification by the
surveillance algorithm.
Conclusion: The empirical definition includes all aspects of CFS specified in the 1994 case definition and identifies
persons with CFS in a precise manner that can be readily reproduced by both investigators and clinicians.
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Chronic fatigue syndrome (CFS) affects 400,000 to
900,000 adults in the United States [1,2]. At least a quarter
of those suffering from CFS are unemployed or receiving
disability because of the illness; the average affected fam-
ily forgoes $20,000 annually in lost earnings and wages
(approximately half of the average United States house-
hold income); and the annual value of lost productivity in
the United States is approximately $9 billion [2-4].
Despite the public health burden imposed by CFS, effec-
tive diagnostic, treatment and prevention strategies are
not available because the etiology, risk factors and patho-
physiology of CFS remain unknown (reviewed in [5]).
To some extent, the inconsistent and often conflicting
results from studies of CFS reflect referral bias. Most pub-
lished studies concerning CFS recruited patients from ter-
tiary referral clinics. Patients receiving care for CFS are
neither similar across clinics [6,7] nor necessarily repre-
sentative of the population of people who suffer from
CFS. Studies of CFS in the general population of Chicago
have found that only 66% of people with CFS have con-
sulted a physician concerning their fatigue and only 19%
of them received a diagnosis of CFS [1]. Studies in the gen-
eral population of Wichita have similarly reported that
only 16% of individuals with the illness have been diag-
nosed by or treated for CFS by a physician [2].
In addition, the lack of consistent findings concerning the
etiology, pathophysiology and risk factors for CFS reflects
lack of standardized reproducible diagnostic criteria for
CFS. CFS is defined as persistent or relapsing fatigue of at
least 6-months' duration, that is not alleviated by rest, and
that causes substantial reduction in activities. The fatigue
cannot be explained by medical or psychiatric conditions
and must be accompanied by at least 4 of 8 case defining
symptoms (unusual post exertional fatigue, impaired
memory or concentration, unrefreshing sleep, headaches,
muscle pain, joint pain, sore throat and tender cervical
nodes) [9]. An International CFS Study Group recently pub-
lished recommendations concerning application of the
case definition [10]. The Group recommended the use of
validated instruments to obtain standardized measures of
the major symptom domains of the illness. They specifi-
cally recommended: (1) the Medical Outcomes Survey
Short Form-36 (SF-36), to measure functional impair-
ment [11]; (2) a comprehensive instrument, such as the
Checklist Individual Strength (CIS) [12] or the Multidi-
mensional Fatigue Inventory (MFI) [13], to obtain repro-
ducible quantifiable measures of fatigue,; and (3) the
CDC Symptom Inventory to document the occurrence,
duration and severity of the symptom complex [14]. We
are aware of no published studies that have utilized this
comprehensive battery of standardized clinically empiri-
cal instruments to characterize persons with CFS, persons
with other unexplained fatiguing illnesses and non-
fatigued controls.
The objective of the present study was to implement rec-
ommendations of the International CFS Study Group [10]
and define CFS based on scores from standardized and
validated instruments that assess the major dimensions of
the illness specified by the 1994 CFS case definition [9].
Data came from a 2-day in-patient study of 227 people
with CFS, with other chronically fatiguing illnesses, and
matched non-fatigued controls identified in the general
population of Wichita, Kansas. We used standardized and
validated instruments to characterize the major dimen-
sions of CFS – functional impairment (SF-36) – fatigue
characteristics (MFI) – frequency and severity of accompa-
nying symptoms (Symptom Inventory).
Methods
Study design
This study adhered to human experimentation guidelines
of the U.S. Department of Health and Human Services
and the Helsinki Declaration. The CDC Institutional
Review Board approved the study protocols (IRB #3504).
All participants were volunteers who gave informed con-
sent.
Recruitment
The study was conducted from December 2002 to July
2003 and enrolled participants, younger than 69 years
from the 1997 through 2000 Wichita CFS Surveillance
Study [2,3,15]. In brief, the Surveillance Study followed a
cohort of 7,162 fatigued and non-fatigued adults repre-
sentative of the Wichita population at 12-, 24-, and 36-
month intervals with telephone interviews and clinical
evaluations.
Two hundred twenty-seven people enrolled in the clinical
study. We invited the 70 people classified as CFS at least
once during the 4-year Surveillance Study; 58 (83%) agreed
to participate. Each CFS case was matched to a control
based on sex, race/ethnicity, age and body mass index.
Matched-controls were selected from the cohort who par-
ticipated in surveillance at the baseline and all follow-up
periods, who did not have medical or psychiatric exclu-
sions, and who had not reported fatigue of at least 1-
month duration; 55 controls participated. We also invited
70 (randomly selected) of the 158 Surveillance Study par-
ticipants identified with unexplained chronic fatigue that
did not meet the criteria for CFS; 59 (84%) agreed to par-
ticipate. We term this group 'insufficient symptoms or
fatigue' (ISF) and discuss it below. Finally, although mel-
ancholic depression is considered exclusionary for CFS,
we invited all 41 surveillance participants who met the cri-
teria for CFS except for concurrent melancholic depres-Page 2 of 9
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(66%) and 28 (72%), respectively, enrolled in the study.
Clinical assessment
Medical evaluation
Those who agreed to participate were admitted to a
Wichita hospital research unit for two days. Hospital staff
was unaware of subjects' enrollment status, as were the
subjects. To identify exclusionary medical conditions
[9,10], subjects provided a standardized past medical his-
tory and review of systems, which they completed at
home. During admission, a study nurse reviewed this and
resolved missing items and patients' questions. Study par-
ticipants brought all current prescribed and over the coun-
ter medications and dietary supplements to the hospital.
These were reviewed and catalogued by a study nurse. At
the time of admission, subjects underwent a standardized
physical examination conducted by a specifically trained
physician. The physician also reviewed past medical his-
tory, review of systems and medications; then, following
the standardized physical examination, she evaluated spe-
cific systems in more detail, as warranted. Finally, patients
provided blood and urine for routine analyses; the study
physician reviewed results the following morning and
considered them in terms of the previous evening's phys-
ical examination. Medical conditions exclusionary for CFS
followed 1994 case definition criteria as modified by the
International CFS Study Group [9,10].
Psychiatric evaluation
Licensed and specifically-trained psychiatric interviewers
administered the Diagnostic Interview Schedule (DIS) to
identify current DSM-IV Axis I psychiatric disorders [16].
Exclusionary psychiatric illnesses included: current mel-
ancholic depression; current or lifetime bipolar disorder
or psychosis; substance abuse within two years and eating
disorders within 5 years [9,10]. Psychiatric disorders con-
sidered non-exclusionary included depression, anxiety
disorders and somatoform disorders.
Evaluation of functional impairment – fatigue – accompanying 
symptoms
Subjects also completed the SF-36 [11], the MFI [13] and
the Symptom Inventory [14] before arriving at the hospi-
tal, at which time the study manager, who resolved miss-
ing responses, reviewed them. The SF-36 assesses
functional impairment in 8 areas: limitations in physical
activities (physical function), limitations in usual role
activities because of physical health problems (role phys-
ical), limitations in usual role activities because of emo-
tional problems (role emotional), bodily pain, general
health perceptions (general health), vitality (energy and
fatigue), social function and general mental health. Scores
in each area reflect function and wellbeing and lower val-
ues indicate more impairment. The MFI assesses general
fatigue, physical fatigue, mental fatigue, reduced motiva-
tion and reduced activity. The score in each dimension
reflects fatigue severity and higher values indicate more
severe fatigue. Finally, the Symptom Inventory assesses
the occurrence, frequency and intensity of 19 symptoms
over the preceding month. For this study, we used the
Symptom Inventory Case Definition Score defined as the
sum of the product of the frequency and intensity scores
of the 8 CFS case defining symptoms [14].
Illness classification
Because study participants had been classified as CFS, ISF
or melancholic depression during surveillance up to 6
years previously and because CFS is cyclic in the occur-
rence and severity of its symptoms, we classified partici-
pants' illness status at the time they participated in the
clinical study. We used two different schemes based on
1994 CFS case definition criteria to classify them.
Illness classification by surveillance criteria
We applied the 1994 case definition algorithm as it had
been used during surveillance to classify subjects. They
completed a questionnaire concerning their illness, it was
reviewed upon arrival at the hospital, and omissions were
rectified. Fatigue fulfilling the case definition was defined
as duration longer than 6 months; and not relieved by rest
(based on a response "a little or not at all" to "Is your
fatigue relieved by Rest?"); and caused substantial reduc-
tion in occupational, educational, social, or recreational
activities (based on a response "a lot" to "Does fatigue
interfere with...?"). The presence of ≥ 4 of the 8 case-defin-
ing symptoms was determined by tabulating positive
responses ("all of the time or most of the time") to queries
concerning the 8 case-defining symptoms (e.g. "During
the past month how often have you had a sore throat?").
Fatigued subjects not meeting fatigue or not meeting
symptom criteria were classified as insufficient symptoms
or fatigue (ISF). Subjects recruited because they were CFS
or ISF during surveillance but who did not report fatigue
at the time of the clinical study were considered in remis-
sion.
Illness classification by standardized clinically empirical criteria
We used information from the SF-36, MFI and Symptom
Inventory to classify subjects empirically according to the
3 main dimensions of CFS: functional impairment (SF-
36), fatigue (MFI) and accompanying symptoms (Symp-
tom Inventory). We defined substantial reduction in occu-
pational, educational, social, or recreational activities as
scores lower than the 25th percentile of published US
population [11] on the physical function (≤ 70), or role
physical (≤ 50), or social function (≤ 75), or role emo-
tional (≤ 66.7) subscales of the SF-36. We defined severe
fatigue as ≥ medians of the MFI general fatigue (≥ 13) or
reduced activity (≥ 10) scales. Finally, subjects reporting ≥Page 3 of 9
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Case Definition Subscale were considered to have sub-
stantial accompanying symptoms.
Subjects who met all 3 criteria (SF-36 and MFI and Symp-
tom Inventory) when they entered the clinical study were
classified as CFS according to standardized clinically
empirical criteria; those who met some but not all 3 crite-
ria were considered as insufficient symptoms or fatigue
(ISF); those who met none of the criteria were classified as
Not Ill.
Statistical analyses
Because classification as CFS at the time of the clinical
study was not completely concordant with recruitment
classification, matching was not maintained. However,
cases and controls were demographically comparable.
We used the χ2-test to compare proportions. We per-
formed 2-step cluster analysis using log-likelihood dis-
tance measures to determine if subjects fell into different
groups according to the SF-36, MFI and Symptom Inven-
tory scales. Differences among fatigue subgroups with
respect to the SF-36, MFI and Symptom Inventory scales
were assessed by one-way analyses of variance followed by
Tukey's pair-wise multiple comparisons method (equal
group variances) or Dunnett's T3 procedure (unequal var-
iances) at a significance level of 0.05. To measure correla-
tions between the SF-36 subscales, MFI subscales and
Symptom Inventory, we used the Pearson correlation
coefficient. We utilized SPSS 11.5 (SPSS Inc., Chicago, IL)
for all analyses.
We used an algorithm developed in Mathematica 5.0
(Wolfram Research, Champaign, IL) to assess the likeli-
hood of global characteristics of the data (the code is
available upon request). The algorithm was based on
principal components analysis and a Monte Carlo
method for computing the mean and variance of the like-
lihood. Information entered into the algorithm included
a matrix of scores for a nominal group (Not Ill) against
which other groups (e.g. CFS, ISF) were compared, and
the minimum difference in SF-36 and MFI scores between
the nominal and other groups. The matrix was divided
into its principal components so that correlations
between the various measurements were accounted for.
Simulations based on the statistical characteristics of the
matrix were performed and the likelihood of seeing a con-
sistent ascending or descending pattern between two or
more groups for all of the SF-36 and MFI scores was eval-
uated.
Results
Enrolment characteristics
Two hundred twenty-seven people participated in the
study and participation rates were similar among the
fatigue categories (p = 0.26). Participants' median age was
51 years (range 25 – 69), 81.9% were women, 94.3% were
white, and 79.3% were overweight or obese (median
body mass index = 29, range 16 – 40). Demographic char-
acteristics did not vary significantly according to recruit-
ment classification (Table 1).
Medical and psychiatric exclusions
We identified 29 people with newly documented medical
conditions considered exclusionary because they could
account for fatigue and accompanying symptoms [9,10].
Medical exclusions included active and inadequately
treated thyroid disease (n = 6), neurological disease (n =
6), inflammatory disease (n = 4), C-reactive protein levels
2 to 4 times normal (n = 3), severe anemia (n = 2), uncon-
trolled diabetes (n = 2), cardiac disease (n = 2), renal dis-
ease (n = 2), breast cancer post-treatment (n = 1) and liver
disease (n = 1). We also identified 4 persons with exclu-
sionary psychiatric conditions; 3 had bipolar disorders (1
person with a bipolar disorder was also medically
Table 1: General characteristics of subjects by recruitment classification.
CFS 
(n = 58)
CFS-MDDm 
(n = 27)
ISF 
(n = 59)
ISF-MDDm 
(n = 28)
Control
(n = 55)
All 
(N = 227)
% Women 86.2 77.8 71.2 92.9 85.5 81.9
Median age (years) 51.5 48.0 50.0 51.5 51.0 51
% White 94.8 92.6 93.2 92.9 96.4 94.3
BMI (%)
<18.5: 
Underweight
1.7 0.0 1.7 0.0 1.8 1.3
18.5–24.9: Normal 13.8 33.3 20.3 21.4 16.4 19.4
25–29.9: 
Overweight
41.4 29.6 32.2 35.7 36.4 34.7
30–34.9: Obese 31.0 29.6 35.6 21.4 34.5 31.7
≥35: Morbidly 
Obese
12.1 7.4 10.2 21.4 10.9 11.9Page 4 of 9
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Finally, 5 subjects could not be classified because DIS data
were missing. These 37 people were not considered fur-
ther in this report.
Twelve fatigued and two control subjects (among the
remaining 190 participants) presented with newly identi-
fied melancholic depression. However, 34 (73.9%) of the
46 subjects enrolled because they had been classified dur-
ing the surveillance study as melancholic depression no
longer had evidence of the condition. Following recom-
mendations of the International CFS Study Group, only cur-
rent MDDm was considered exclusionary for CFS. Thus,
the remainder of this paper discusses only the 164 partic-
ipants with no medical or psychiatric exclusionary condi-
tions.
Illness classification by surveillance criteria
When we applied the same case definition algorithm used
in the surveillance study to classify subjects at the time
they entered this clinical study only 16 had a current clas-
sification of CFS, 76 of ISF, 48 were not fatigued controls,
and remission was identified in 24 recruited as CFS/ISF
who no longer reported fatigue (Table 2). Most (87%) of
the 46 subjects enrolled because they were considered CFS
during surveillance did not meet the same case definition
criteria at the time of the clinical study: most (58.7%)
were classified as ISF and 10.9% were in remission. This
difference was less striking among those recruited as ISF:
64.6% retained their ISF classification; but 18.8% were in
remission and 8.3% were assigned a current classification
of CFS.
Table 2: Recruitment and Current Classifications of 190 Subjects; 37 participants with medical or psychiatric exclusions other than 
melancholic depression excluded.
Current Classification by Surveillance Criteria
Classification 
During 
Surveillance
CFS ISF Remission Control Exclusions
CFS 6 (13.0) 27 (58.7) 5 (10.9) 0 8 (17.4) 46
ISF 4 (8.3) 31 (64.6) 9 (18.8) 0 4 (8.3) 48
Control 0 0 0 48 (96.0) 2 (4.0) 50
CFS MDDm 5 (23.8) 9 (42.9) 2 (9.5) 0 5 (23.8) 21
ISF MDDm 1 (4.0) 9 (36.0) 8 (32.0) 0 7 (28.0) 25
16 76 24 48 26 190
Columns show number of subjects and (percent of row)
Table 3: Characteristics of 2-steps 3-cluster analysis solution for 164 subjects with no medical or psychiatric exclusions.
Characteristic Cluster 1 Most Severe (n = 30) Cluster 2 Intermediate (n = 67) Cluster 3 Least Severe (n = 67)
SF-36 Scales (mean ± sd)
Physical function 49.5 ± 21.8 71.8 ± 20.1 91.0 ± 10.3
Role physical 12.5 ± 26.9 48.1 ± 36.0 92.5 ± 19.5
Bodily pain 39.5 ± 18.3 53.7 ± 16.5 79.4 ± 15.6
General health 45.4 ± 19.3 67.4 ± 13.8 85.3 ± 12.6
Vitality 14.3 ± 11.0 34.6 ± 15.8 69.6 ± 16.0
Social function 45.4 ± 24.0 67.9 ± 18.4 96.3 ± 8.7
Role emotional 47.8 ± 41.7 74.1 ± 35.2 96.0 ± 13.6
Mental health 61.5 ± 19.5 74.4 ± 13.5 86.9 ± 9.1
MFI Scales (mean ± sd)
General fatigue 18.4 ± 1.4 15.1 ± 2.7 8.7 ± 3.2
Physical fatigue 15.4 ± 2.7 11.6 ± 2.8 6.7 ± 2.1
Mental fatigue 15.9 ± 3.5 10.3 ± 3.9 6.6 ± 2.7
Reduced motivation 13.4 ± 4.0 10.3 ± 3.0 6.2 ± 2.0
Reduced activity 15.8 ± 3.3 11.9 ± 3.5 5.9 ± 2.0
Symptom Inventory (mean ± 
sd)
52.2 ± 24.8 21.6 ± 12.6 7.0 ± 8.5
All clusters were significantly different from the other clusters with respect to all scalesPage 5 of 9
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lance and diagnosis by surveillance criteria at the time of
the in-hospital study could reflect the cyclic nature of CFS
and changes over time. So we used an independent
approach to evaluate the current overall severity of illness.
To do this we applied a 2-step cluster analysis to scores
from the 8 SF-36, 5 MFI and Symptom Inventory Case
Definition scale scores. These 14 interrelated scores reflect
overall severity of illness and 3 distinct clusters emerged
(Table 3). The most severely ill subjects, with the lowest
SF-36, highest MFI and highest Symptom Inventory scores
were in cluster-1. Cluster-3 included the least severely ill
subjects, whose scores essentially reflected population
norms. Cluster-2 represented intermediate illness severity.
Most (89.6%) of the non-fatigued controls were in the
least severely ill cluster, but 5 controls (10.4%) were in the
intermediate severity cluster; CFS, ISF and remission were
spread across all 3 clusters (Table 4).
Illness classification by standardized clinically empirical 
criteria
Finally, we classified study participants by standardized
clinically empirical criteria and found little agreement
within subjects according to their classification at the time
of this study by surveillance criteria (Table 5). To explore
the characteristics of people classified by the standardized
clinically empirical criteria, we evaluated associated SF-
36, MFI and Symptom Inventory scores.
SF-36
Persons with fatiguing illnesses showed significantly more
functional impairment (lower scores) in all 8 scales of the
SF-36 compared to the Not Ill (Table 6). Those with CFS
had significantly lower scores on all SF-36 subscales than
those with ISF (all post-hoc-comparisons: p < 0.001;
except role-emotional p = 0.027 and mental health p =
0.050).
MFI
Persons with fatiguing illnesses had significantly higher
scores on all scales (indicating more severe fatigue) than
Not Ill (Table 6). Consistent with the SF-36, those with
empirically defined CFS had significantly higher scores on
all MFI subscales than subjects with ISF (all post-hoc-
comparisons p < 0.001; except reduced motivation p =
0.016).
Symptom inventory
The Symptom Inventory reflected similar associations
(Table 6). Fatigued persons had significantly higher
Symptom Inventory scores than the Not Ill (p < 0.001)
and subjects with CFS had significantly higher scores than
those with ISF (post-hoc-comparison p < 0.001).
Monte Carlo analysis
We used a Monte Carlo analysis to assess the likelihood of
seeing this global pattern of significant differences
between empirically defined CFS and ISF and Not Ill on
Table 4: Current classification and illness severity by cluster analysis of 164 study participants with no medical or psychiatric 
exclusions.
Cluster Group
Current Classification 
Surveillance Criteria
1 Most Severe 2 Intermediate 3 Least Severe
CFS 7 (43.8)* 9 (56.3) 0 16
ISF 16 (21.1) 55 (72.4) 5 (6.6) 76
Remission 1 (4.2) 13 (54.2) 10 (41.7) 24
Control 0 5 (10.4) 43 (89.6) 48
24 82 58 164
* percent of row
Table 5: Illness classification at the time of the clinical study by surveillance criteria and by standardized clinically empirical criteria of 
164 study participants with no medical or psychiatric exclusions.
Current Classification 
Surveillance Criteria
CFS ISF Not Ill
CFS 10 (62.5) 6 (37.5) 0 16
ISF 32 (42.1) 38 (50.0) 6 (7.9) 76
Remission 1 (4.2) 13 (54.1) 10 (41.7) 24
Control 0 4 (8.3) 44 (91.7) 48
43 61 60 164
Columns show number of subjects and (percent of row)Page 6 of 9
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probabilities that each group would separate from the
others by such a wide margin on all scales by chance alone
were vanishingly small (p < 10-7). Even the consistent dif-
ference between the Not Ill and ISF groups on all 14 scores
was extremely unlikely (p < 0.0001). This likelihood was
great enough, however, that up to 10 of the not fatigued
people from the screening sample (56,000) could have
been clustered with the ISF group due to random variation
within the Not Ill population (given the mean plus 3
standard deviations in the estimate of the variance on all
scales from the Not Ill population). That is, some of the
movement (Table 5) from control to ISF, and likewise ISF
to CFS, could have resulted from classification of individ-
uals at the extreme end of the bell curve of one population
as being members of a different population with a differ-
ent illness state.
Discussion
The primary objective of this study was to implement rec-
ommendations of the International CFS Study Group [10]
and define CFS on the basis of scores from standardized
and validated instruments that assess the major dimen-
sions of the illness as specified by the 1994 CFS case defi-
nition [9]. Functional impairment, fatigue and an
accompanying symptom complex characterize CFS. We
defined functional impairment as scores ≤ 70 on the phys-
ical function or ≤ 50 on the role physical or ≤ 75 on the
social function or ≤ 66 on the role emotional subscales of
the SF-36. We defined severe fatigue as scores ≥ 13 on the
general fatigue or ≥ 10 on the reduced activity subscales of
the MFI. Finally, we defined the accompanying symptom
complex as reporting the occurrence of ≥ 4 of 8 symptoms
and scoring ≥ 25 on the Symptom Inventory Case Defini-
tion subscale. One could debate our choice of specific
subscales from the SF-36 and MFI and the specific cut-off
values we chose on the SF-36, MFI and Symptom Inven-
tory. However, these instruments have been validated,
have been used extensively in studies of CFS and other ill-
nesses, and are known to be reproducible. In contrast,
most studies of CFS merely note that they used the 1994
case definition and they do not generally specify how dis-
ability, fatigue and symptom occurrence were elucidated.
Thus, it is difficult to assess the validity of their diagnostic
criteria and essentially impossible to compare results
between studies critically.
This study showed scant stability of CFS over time, when
diagnosed by the usual algorithm (based on patients' sub-
jective responses to direct questions as to whether they
feel fatigued, if they perceive their fatigue causes substan-
tial reduction in daily activities, and whether at least 4
case defining symptoms are present). There was poor cor-
relation between illness classification during surveillance
(recruitment classification) and classification by the same
criteria during the clinical study. While this might reflect
fluctuation in illness over time, illness categories (CFS,
ISF, Remission, non-fatigued) defined by this surveillance
classification scheme were not consistent with respect to
overall illness severity. In contrast, when we defined ill-
Table 6: Medical Outcomes Study Short-Form 36 (SF-36), Multi-Dimensional Fatigue Inventory (MFI) and Symptom Inventory Scores 
according to current illness classified by standardized clinically empirical criteria in 164 participants with no exclusionary medical or 
psychiatric conditions.
Scale CFS ISF Not Ill
SF-36
Physical function+ 53.3 ± 21.5 * 77.5 ± 18.9 89.7 ± 13.2
Role physical+ 18.0 ± 28.5 * 60.7 ± 37.2 88.8 ± 25.0
Bodily pain 41.7 ± 15.7 * 59.7 ± 20.0 77.9 ± 16.0
General health 51.2 ± 20.4 * 70.1 ± 13.6 85.2 ± 13.3
Vitality 18.6 ± 12.5 * 37.3 ± 18.5 72.3 ± 13.0
Social function+ 50.0 ± 22.7 * 74.2 ± 19.6 94.8 ± 10.6
Role emotional+ 55.8 ± 42.2 * 76.5 ± 33.5 96.1 ± 13.8
Mental health 66.4 ± 18.5 * 74.6 ± 14.0 87.5 ± 9.0
MFI
General fatigue+ 18.5 ± 2.1 * 14.9 ± 2.7 8.0 ± 2.6
Physical fatigue 14.1 ± 3.2 * 11.0 ± 3.2 6.8 ± 2.2
Mental fatigue 14.1 ± 4.2 * 10.0 ± 4.3 6.6 ± 2.6
Reduced motivation 12.2 ± 3.8 * 10.1 ± 3.3 6.1 ± 2.0
Reduced activity+ 14.7 ± 3.1 * 11.5 ± 4.0 5.6 ± 1.6
Symptom Inventory+ 47.3 ± 22.0 * 18.6 ± 11.9 6.1 ± 7.1
+Indicate subscales used in validated clinically empirical CFS case definition
Scores are mean ± standard deviation
Bolded figures indicate that specific group scores are significantly different (p < 0.05) from non-fatigued scores.
* indicates that CFS scores are significantly different from ISF scores
Note: Low scores in the SF-36 indicate more severe conditions, whereas in the MFI higher scores indicate more severe conditions.Page 7 of 9
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dated clinically empirical instruments, we found an
extremely strong relationship between diagnostic category
and every measure of severity. It is not surprising that
scores on the 4 SF-36 and 2 MFI scales used in classifica-
tion were significantly correlated with diagnosis, but the 4
SF-36 and 3 MFI scales not used in classification showed
similar significant associations with diagnostic category.
Although correlated, the dimensions of impairment and
fatigue defined by these instruments represent statistically
independent factors. Finally, while only 13% of patients
who met the 1994 case definition criteria during surveil-
lance met those same criteria in the present study, 40%
fulfilled CFS criteria of the clinically empirical definition.
Thus, the clinically empirical case definition may be less
affected by the day-to-day fluctuation of the illness and
rather reflect the underlying chronic illness process.
Defining CFS in this empirical manner will improve the
precision of case ascertainment in research studies, it will
provide a standard reproducible means of following the
clinical course over time, and it will help to clarify the
extent to which patients from different referral clinics are
similar (or dissimilar). Finally, this strategy can be used in
primary care settings and will give health care providers a
standard and reproducible method for diagnosing CFS.
The SF-36, MFI and Symptom Inventory are relatively
short forms that are completed by patients: scoring is
straightforward and can be accomplished by clinic staff.
The MFI and Symptom Inventory are in the public
domain but the SF-36 is sold under license.
Use of this diagnostic strategy also provides health care
providers with objective measures of the disability associ-
ated with CFS. The SF-36 measures functional impairment
in 8 distinct dimensions. Normative values have been rig-
orously derived and documented in each dimension for
healthy individuals and in a wide variety of disease states
[11,17,18]. For example, in this study subjects with empir-
ically defined CFS had lower scores on all scales, except
physical function and general health, than those of
patients with congestive heart failure. In addition to doc-
umenting impairment, scores on individual components
of the SF-36 and MFI can be used to identify specific
aspects of the illness for specific interventions and
changes in scores over time can be used to monitor
response to therapeutic interventions.
In addition, there is a certain mathematical appeal to the
new criteria. Principal components analysis of the matrix
of 14 scores (8 SF-36, 5 MFI, and the Symptom Inventory
Case Definition subscale) for those enrolled in this study
showed that their symptoms define a roughly 3-dimen-
sional space (rather than 14) and the first 3 principal com-
ponents accounted for 76% of the total variation among
individuals. These 3 components roughly align with the
most significant scales of the SF-36, MFI and Symptom
Inventory, all of which are part of the 3 inequalities we
used to empirically classify illness. As a consequence, the
3 components cleanly separate the empirically classified
groups of CFS, ISF and Not Ill in 3-dimensional space,
whereas this separation could not be achieved with the
older classification scheme
Finally, our findings highlight the importance of contin-
ued evaluation of persons with CFS. Clinical management
of CFS poses a difficult challenge for health care providers,
patients and patients' families/associates because of the
absence of physical signs and because illness severity and
symptoms vary dramatically over time. Not all new symp-
toms or worsening of severity should be attributed to CFS
a priori. Thirty-two (13%) of the study participants had
serious medical or psychiatric diseases diagnosed for the
first time during this study and another 18 (7%) were
newly discovered to have melancholic depression, thus
supporting inclusion of this disease in the exclusionary
criteria. Those 49 subjects had been repeatedly evaluated
during the Wichita surveillance study and had no prior
evidence of such conditions.
Conclusion
In conclusion, we found that CFS can be defined by use of
readily available instruments that evaluate the major com-
ponents specified in the 1994 case definition. People with
CFS defined in this manner are clinically distinct from
those with unexplained fatigue (i.e. ISF) that does not
meet the criteria for CFS. Future research studies should
define CFS in this manner and this diagnostic strategy can
also be used for the clinical evaluation and subsequent
follow-up of patients with CFS.
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